| Business Summary | | AP
Pharma
Inc.,
formerly
known
as
Advanced
Polymer
Systems,
Inc.,
is
a
specialty
pharmaceutical
company
focused
on
the
development
of
ethical
(prescription)
pharmaceuticals
utilizing
its
proprietary
polymer-based
drug
delivery
systems.
The
Company's
primary
focus
is
the
development
and
commercialization
of
its
bioerodible
injectable
and
implantable
delivery
systems
under
the
trade
name
Biochronomer.
Initial
targeted
areas
of
application
for
the
Company's
technologies
include
pain
management,
inflammation,
oncology,
ophthalmology
and
orthopedic
applications.
The
Company's
product
development
programs
are
funded
by
royalties
from
topical
products
currently
marketed
by
pharmaceutical
partners. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | AP
Pharma
Inc.
is
a
leader
in
polymer-based
delivery
systems
and
related
technologies
with
a
broad
proprietary
and
intellectual
property
platform.
For
the
six
months
ended
6/30/01,
total
revenues
rose
23%
to
$2
million.
Net
loss
from
continuing
operations
rose
21%
to
$2.1
million.
Revenues
reflect
increased
royalty
sales
of
Retin-A(R)-Micro(TM)
and
Carac(TM).
Higher
loss
reflects
increased
R&D
expenses
for
the
new
bioerodible
Biochronomer
(TM)
delivery
systems. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Paul Goddard, Ph.D., 51 Chairman | -- | Michael O'Connell, 51 Pres,
CEO | $400K | Gordon Sangster, 47 CFO | 252K | John Barr Ph.D VP-R&D | 161K | Jayne Lange VP-Bus.
Devel. | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|